Total-body scintigraphy with 131I-meta-iodobenzylguanidine for detection of neuroblastoma.
Total-body scintigraphy with 131I-meta-iodobenzylguanidine (131I-MIBG) was performed in 20 patients with neuroblastoma. In patients who were in complete remission no pathological concentration of 131I-MIBG was found. In 16 patients with residual, recurrent or metastatic neuroblastoma the tumor localizations were correctly identified by 131I-MIBG-scintigraphy In 5 patients additional tumor sites were found. In most patients an inverse relationship between myocardial and tumoral concentration of 131I-MIBG was noted. Dosimetric assessment of 131I-MIBG uptake in patients with metastatic disease revealed cases with considerable tracer concentration and long effective half lives in tumor localizations. It is concluded that 131I-MIBG total-body scintigraphy is useful in the diagnosis and follow-up of neuroblastoma and that therapeutic use of this agent is feasible, if patients are selected upon the merits of dosimetry.
D019797:3-Iodobenzylguanidine; D000008:Abdominal Neoplasms / Q000000981:diagnostic imaging*; D000310:Adrenal Gland Neoplasms / Q000000981:diagnostic imaging; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D008297:Male; D009447:Neuroblastoma / Q000000981:diagnostic imaging* / Q000556:secondary; D011877:Radionuclide Imaging; D013565:Sympatholytics; D014915:Whole-Body Counting
D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D013565:Sympatholytics; D019797:3-Iodobenzylguanidine